Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2000
12/13/2000CN1059442C Use of 1,2-bridged 1,4-dihydropyridines as medicaments
12/13/2000CN1059441C Benzopyranols, their preparing method, and their pharmaceutical composition and use
12/13/2000CN1059433C Arylalkyl (thio) carboxamides, processes forpreparing them and pharmaceutial composition contg. them
12/13/2000CN1059336C Oral liquid for treatment of senile dementia and constipation
12/12/2000US6160133 Stereospecific biosynthesis of the alcohol by enzymatic reduction of the corresponding aldehyde or ketone using a candida, zygosaccaromyces, or mortierrela microorganism
12/12/2000US6160123 One pot synthesis of 2-oxazolidinone derivatives
12/12/2000US6160106 Nucleotide sequences which code polypeptides which prevent gene expression; for use as diagnostic screening tools in the detection and treatment of cancer; anticarcinogenic agents
12/12/2000US6160015 Administering to mammal a farnesyl protein transferase inhibitor
12/12/2000US6160009 Excitatory amino acid receptor modulators
12/12/2000US6159998 Administered as vasodilators, analgesics, anesthetics, sedatives, and anitspasmodic agents
12/12/2000US6159987 Bicyclolactam compounds, use thereof and intermediates for preparing thereof
12/12/2000US6159981 3-substituted pyrido [3',4':4,5] Thieno [2,3-d] pyrimidine derivatives, and production and use of the same
12/12/2000US6159980 Anxiolytic agents, antidepressants; psychological and eating disorders
12/12/2000US6159979 Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity
12/12/2000US6159972 Enzyme inhibitors
12/12/2000US6159971 Combination of a 5-HT reuptake inhibitor and a h5-HT1B anatagonist or partial agonist
12/12/2000US6159970 Enzyme inhibitors
12/12/2000US6159967 such as 1-(2-((2R)-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl) morpholin-2-yl)ethyl)spiro(benzo(c)thiophene-1-(3H), 4'-piperidine)-(2S)-oxide; respiratory disease such as asthma
12/12/2000US6159962 3-substituted 3,4-dihydro-thieno[2,3-D]pyrimidine derivatives and production and use of the same
12/12/2000US6159958 Treatment or prophylaxis of retinal pathology and spinal cord injury
12/12/2000US6159716 Amino acid sequence of serine/threonine kinase; antiulcer/ anticarcinogenic/antiarthritic agents; treatment of parkinson's/huntigton's diseases, tourette's syndrome, eating disorders, osteoporosis, allergies; diagnosis of disease
12/12/2000US6159461 Use of c-kit ligand with TNF-α and hematopoietic factors for the expansion or differentiation of hematopoietic cells
12/12/2000CA2168247C Nitric oxide donor composition and method for treatment of anal disorders
12/07/2000WO2000073788A1 Use of gabapentin in assays to identify gabab receptor modulators
12/07/2000WO2000073764A2 Composition and methods for the therapeutic use of an atonal-associated sequence
12/07/2000WO2000073501A2 Nucleic acid molecules with specific identification of native prpsc, their production and the use thereof
12/07/2000WO2000073482A1 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
12/07/2000WO2000073469A2 Protein kinases
12/07/2000WO2000073463A1 Groel muteins with improved stability
12/07/2000WO2000073450A2 Cytoskeleton-associated proteins
12/07/2000WO2000073449A1 Dna encoding snorf33 receptor
12/07/2000WO2000073344A2 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
12/07/2000WO2000073342A1 Structural models for cytoplasmic domains of transmembrane receptors
12/07/2000WO2000073337A1 Polymer conjugates of hedgehog proteins and uses
12/07/2000WO2000073334A2 Human sorting nexins
12/07/2000WO2000073327A1 Chemokine receptor ccr3 antagonists
12/07/2000WO2000073324A2 Modulation of gene expression in gastrointestinal inflammation
12/07/2000WO2000073323A2 Adam polynucleotides and polypeptides
12/07/2000WO2000073321A1 Human tumor necrosis factor receptor tr10
12/07/2000WO2000073313A1 New tricyclic amidine derivatives as inhibitors of nitric oxide synthase
12/07/2000WO2000073309A1 Pyrozolo [3,4-d][1,2,3] triazines with an anticonvulsive action and methods for producing the same
12/07/2000WO2000073306A1 2-arylpurine-9-acetamide derivatives, process for the preparation thereof, medicinal compositions containing the same and intermediates of the derivatives
12/07/2000WO2000073303A1 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists
12/07/2000WO2000073300A1 Amino heterocycles useful as pharmaceutical agents
12/07/2000WO2000073299A1 Sulfonamide compounds with pharmaceutical activity
12/07/2000WO2000073296A2 3-heteroarylalkyl substituted gaba analogs
12/07/2000WO2000073295A1 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides
12/07/2000WO2000073294A2 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides
12/07/2000WO2000073283A1 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
12/07/2000WO2000073279A1 4-phenyl-pyrimidine derivatives
12/07/2000WO2000073278A2 5-phenyl-pyrimidine derivatives
12/07/2000WO2000073275A1 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
12/07/2000WO2000073269A2 Nicotine receptor ligands
12/07/2000WO2000073266A1 Novel antioxidants, preparation methods and uses
12/07/2000WO2000073259A1 Fused polycyclic amino acids as pharmaceutical agents
12/07/2000WO2000072881A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
12/07/2000WO2000072880A2 Prevention and treatment of amyloidogenic disease
12/07/2000WO2000072876A2 Prevention and treatment of amyloidogenic disease
12/07/2000WO2000072871A1 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area
12/07/2000WO2000072870A1 Compositions of a-beta peptide and processes for producing same
12/07/2000WO2000072863A2 Uses of h-trek-1 polypeptides and polynucleotides encoding them
12/07/2000WO2000072861A1 Pharmaceutical preparations of bioactive substances extracted from natural sources
12/07/2000WO2000072847A1 Ziprasidone suspension
12/07/2000WO2000072845A1 Il-8 receptor antagonists
12/07/2000WO2000072844A1 Neuronal death inhibitors
12/07/2000WO2000072843A1 Therapeutic use of melatonin
12/07/2000WO2000072842A1 Nutritional supplements
12/07/2000WO2000072841A1 Compounds and methods for the treatment of post traumatic stress disorder
12/07/2000WO2000072840A1 Il-8 receptor antagonists
12/07/2000WO2000072834A2 Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
12/07/2000WO2000072832A2 Novel use of 1-[4-(cyanoindol-3yl)butyl]-4-(carbamoyl-benzofuran-5yl)-piperazine and its physiologically acceptable salts
12/07/2000WO2000072815A1 Indole derivatives
12/07/2000WO2000050568A3 Transplantation of haematopoietic cells
12/07/2000WO2000048584A3 Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain
12/07/2000WO2000045801A3 Use of a nitrate vasodilator alone or in combination with capsaicin for the treatment of pain
12/07/2000WO2000042996A3 Use of anticonvulsant derivatives for treating cluster headaches
12/07/2000WO2000041681A3 MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
12/07/2000WO2000024390A9 Method and composition for modulating amyloidosis
12/07/2000WO2000009104A3 Use of sulfonamides for treating vision and memory disorders
12/07/2000CA2694866A1 Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
12/07/2000CA2414094A1 Pharmaceutical preparations of bioactive substances extracted from natural sources
12/07/2000CA2383244A1 Protein kinases
12/07/2000CA2376024A1 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
12/07/2000CA2375855A1 Modulation of gene expression in gastrointestinal inflammation
12/07/2000CA2375827A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
12/07/2000CA2375700A1 Polymer conjugates of hedgehog proteins and uses
12/07/2000CA2375683A1 Il-8 receptor antagonists
12/07/2000CA2375348A1 Novel antioxidants, preparation methods and uses
12/07/2000CA2375196A1 Use of gabapentin in assays to identify gabab receptor modulators
12/07/2000CA2375186A1 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
12/07/2000CA2375123A1 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
12/07/2000CA2375106A1 Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
12/07/2000CA2375104A1 Prevention and treatment of amyloidogenic disease
12/07/2000CA2375095A1 Groel muteins with improved stability
12/07/2000CA2375047A1 Dna encoding snorf33 receptor
12/07/2000CA2374921A1 Neuronal death inhibitors
12/07/2000CA2374897A1 Compositions of a-beta peptide and processes for producing same
12/07/2000CA2374310A1 Nutritional supplements
12/07/2000CA2374295A1 Il-8 receptor antagonists
12/07/2000CA2374222A1 Cytoskeleton-associated proteins
1 ... 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 ... 1833